PPT-CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Program Overview EMPAREG OUTCOME Trial Design EMPAREG OUTCOME Primary Endpoint 3Point MACE EMPAREG OUTCOME CV Death EMPAREG OUTCOME CV Death Nonfatal MI and Nonfatal Stroke EMPAREG OUTCOME . Chapter 5. Thomas . Ransom, Ronald Goldenberg, Amanda . Mikalachki. , Ally . PH . Prebtani. , . Zubin. . Punthakee. Canadian Diabetes Association 2013 Clinical Practice Guidelines. Key Points. At this time, there are no safe and effective strategies to prevent T1DM. Donald P. Callahan. President & CEO. Guy Carpenter Canada. Risk Officers Forum Meeting. November 23, 2016. A CEO’s Perspective on Risk Management. Donald P. Callahan. President & CEO. Guy Carpenter Canada. Describe different types of risk.. The Main Idea. Everybody faces risk that can lead to loss, injury, or even death. Individuals and businesses can use strategies to manage risk as ways to reduce or avoid loss.. 1. AACE Comprehensive Diabetes Care: Glucose Goals . Parameter. Treatment Goal for . Nonpregnant. Adults. A1C (%). . Individualize based on age, comorbidities, and duration of disease*. ≤6.5 for most. Proposed . Solutions And Improvement Initiatives. Jan Ambergen, . Treasury Director. 23. rd. May 2016. Content: “Risk Walk Through”. Company overview. Business Risk Inventory. External risks . Operational risks. Program Goal. Case Presentation: Diane. Case Presentation (cont). ADA/EASD Position Statement. ADA/EASD Position Statement: Glycemic Targets. ADA/EASD Position Statement on Therapeutic Options: Lifestyle. Introduction/Overview. Lowering HbA1c Reduces the Risk of Microvascular Complications -- But What About Macrovascular Complications?. December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM . Disease. . s_khalilzadeh. A Novel. Cardiometabolic Risk Factor for Type 2 Diabetes. NAFLD and T2DM. NAFLD is closely associated with features of the metabolic. syndrome and is regarded as the hepatic manifestation. Prediabetes. Consensus Statement: Summary. Untreated individuals with . prediabetes. are at increased risk for diabetes as well as for micro- and . macrovascular. complications. Treatment goals are to prevent deterioration in glucose levels and modify other risk factors such as obesity, hypertension, and dyslipidemia . The . aim . of the association . is . to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. CVOT-based ADA/EASD . recommendations 2020. Växjö 2019-02-13. Maria . Thunander. Överläkare, med dr. Medicinkliniken, Centrallasarettet Växjö. FoU, Region Kronoberg. Institutionen för . Klin. Vetenskaper, Lunds Universitet. 1. Clinical . Backgrounde International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM) []. People with diabetes comprise 8.8% by Sun H. Kim, MD MS. Associate Professor of Medicine. Division of Endocrinology, Gerontology, and Metabolism. March 29, 2022. This Community Health Talk Series was made possible through the generous support of the Vincent V.C. Woo Memorial Foundation.. Research Institute for Endocrine Sciences. Shahid. . Beheshti. University of Medical Sciences. 21 July 2016. Nonalcoholic Fatty Liver Disease . Case Discussion . 2. Case 1. Case 1. A generally healthy 42 y/o lady came to you for evaluation of fatty liver (grade I) discovered during a routine abdominal ultrasound..